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1. Introduction
As per the American Diabetes Association, 2-3 million individuals in the United States have
type 1 diabetes (www.medicinenet.com/script/main/art.asp?articlekey=159355), with 1 in
every 400 to 600 children and adolescents affected by the disease in 2007. Furthermore, similar
to other autoimmune diseases, allergies and asthma, the incidence of type 1 diabetes is on the
increase at an alarming rate in industrialized countries for unknown reasons. Information
released by the American Diabetes Association shows 23% and 21% increased rates of type 1
and 2 diabetes, respectively, from 2001 to 2009. The increase in incidence of type 1 diabetes is
especially apparent in young children and has generated an urgent need for novel treatments
that can safely control diabetes-causing inflammation, and alleviate the need for administra‐
tion of exogenous insulin. Indeed, type 1 diabetes has been treated for almost a century in the
same fundamental manner using daily insulin injections. Although it is a life-saving treatment
and one of the most remarkable accomplishments of medicine, administration of exogenous
insulin is still not a cure because it does not address the underlying autoimmunity that targets
insulin-secreting beta cells. Because it is currently impossible to mimic regulation of physio‐
logical insulin levels faithfully, many type 1 diabetic individuals receiving standard of care
are exposed to acute and chronic complications that cause increased morbidity and mortality.
As a result, there have been intense efforts to develop immunotherapies that can eliminate or
at least alleviate the need for exogenous insulin. In this case the goal is to arrest pathological
autoimmunity that destroys beta cells so that the cells can regain function, and possibly
proliferate and regenerate.
Two major immunotherapeutic paths have been taken. The first path relies on different forms
of systemic suppression of inflammation that inhibit effector T lymphocytes in a non-specific
manner. Serious side effects associated with the use of systemic immunotherapies are in‐
creased risks of cancer and infection resulting from the decreased activity of effector cells
involved in beneficial destructive immune responses against cancer cells and pathogens. These
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side effects have been observed with broadly acting immunosuppressants used to prevent
organ transplant rejection, which have been also investigated for treating type 1 diabetes [1,
2]. Serious side effects can also be seen, albeit to a lesser degree, with more specific agents like
antibodies that target specific molecules involved in inflammation [3, 4]. In contrast, the second
immunotherapeutic path is based on administration of a self-antigen synthesized by pancreatic
beta cells that is a target of pathological autoimmunity, i.e., an autoantigen. This path is thought
to be safer because it aims to induce a regulatory immune response that targets the inflamed
islets. Here the goal is to manipulate endogenous immune mechanisms of homeostasis that
can re-establish some form of tolerance to the chosen autoantigen, as well as to other neigh‐
boring beta cell autoantigens through a mechanism known as “by-stander suppression” [5].
Accordingly, it is anticipated that pathological autoimmunity and inflammation of islets can
be stopped in an organ-specific manner that does not impair the immune system.
In this chapter, we will review how plasmid deoxyribonucleic acid (DNA) has been used as
an immunotherapeutic vector platform to treat type 1 diabetes through each immunothera‐
peutic path. For the purpose of this review, we have called the first path “gene-based immu‐
notherapy”, meaning that plasmid DNA does not encode a known autoantigen, and the second
path “DNA vaccine immunotherapy” meaning that a beta cell autoantigen is encoded by
plasmid DNA (Figure 1). In other words, gene-based immunotherapy relies on the inherent
function of a product encoded by plasmid DNA that can in turn affect cell function. In contrast,
DNA vaccine immunotherapy relies on the tolerogenic immune response induced directly by
the autoantigen after its processing by immune cells. As we shall see, some DNA vaccine
immunotherapies have also a gene-based immunotherapy component that acts as a molecular
adjuvant to promote tolerogenic immune responses. Nevertheless, in all cases synthesis of the
molecule encoded by plasmid DNA, which is almost always a protein, starts after delivery of
the plasmid DNA and its uptake by cells.
Plasmid DNA has several notable advantages compared to other vectors and therapeutic
molecules. For example, it consists of relatively low molecular weight circles of double
stranded DNA that can be readily isolated from bacteria in a generic and cost-effective manner.
In addition, plasmid DNA permits rapid turnaround when developing new candidate
products, refrigeration-free storage, and synthesis over time of a chosen antigen in its native
conformation. Furthermore, plasmid DNA can be given in repeat doses within short periods
of time without inducing an immune response to vector and other side effects. This is in
contrast with viral-based vaccines that can induce immune responses to vector and protein/
peptides that can cause anaphylaxis [6, 7].
Plasmid DNA can be delivered either as “naked” DNA or packaged into molecular scaffolds
like liposomes, cationic lipids, virosomes, and polymer-based nano- and micro-particles to
increase efficacy of delivery to cells [8]. Although they may sometime have pro-inflammatory
properties that can be detrimental to controlling inflammation, these particles have been used
to induce immune tolerance with plasmid DNA. For example, chitosan-DNA nanoparticles
encoding an ovalbumin antigen are tolerogenic when delivered orally [9].
Indeed, route of delivery can play a significant role in the type and strength of immune
responses induced by DNA vaccines in animal models [10, 11]. In humans, two microgram of
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a DNA vaccine for treatment of melanoma delivered with gold particles into skin was found
to be as efficacious as 1000 microgram injected intramuscularly [12]. These results illustrate
the significant impact that choice of route and method of delivery of a DNA vaccine can have
not only on efficacy, but also on cost of treatment. Other delivery routes like intravenous, nasal,
and sublingual have also been investigated [13]. Post delivery, expression of coding sequences
in plasmid DNA results in significant levels of protein production that may persist for six
weeks and longer without serious side effects in human patients [14, 15].
Figure 1. Plasmid DNA Immunotherapy for Type 1 Diabetes. Plasmid DNA immunotherapy for type 1 diabetes can
be divided into two categories: DNA vaccines and gene therapies. Plasmid DNA can be delivered using different
routes, for example, the intradermal and intramuscular routes. The therapies can induce tolerogenic dendritic cells
(DC), T regulatory cells (Treg), and death/anergy of T effector cells (Teff) which are the main cause of pancreatic islet
destruction.
DNA vaccination was originally investigated to induce immunogenic responses to pathogens
and cancer cells, but it has increasingly been applied to the induction of immune tolerance for
treatment of autoimmune diseases like type 1 diabetes. DNA vaccines and other gene-based
vaccines belong to a third generation of vaccines after live and attenuated whole organism
vaccine and recombinant protein vaccines. These vaccines can be used to either prevent
(prophylactic vaccine) or treat (therapeutic vaccine) disease depending on their potency, in
which prevention is generally easier to achieve than treatment. Recent reports of beneficial
results in different clinical trials using delivery of autoantigens indicate that DNA vaccination
is reaching a stage where we are likely to see accelerated development of a therapeutic future
for vaccines targeting a variety of autoimmune diseases. In the case of type 1 diabetes, early
results using a DNA vaccine encoding insulin have shown promise in humans. In addition,
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DNA vaccines encoding human heat shock protein 60 and glutamic acid decarboxylase 65 have
also shown efficacy in preclinical trials and are reviewed in this chapter.
In contrast to DNA vaccine immunotherapy, gene-based immunotherapy involves delivery
of genetic material by a plasmid vector into a cell, tissue or organ with the aim of improving
the clinical status using the function of the encoded product, instead of its properties as an
antigen. Gene-based immunotherapy includes delivery of anti-inflammatory cytokines,
chemokines, and other factors to modulate the activity of immune cells [16, 17].
2. Gene-based immunotherapies
Several pre-clinical trials have used plasmid DNA-based gene therapies in experimental
models of autoimmune type 1 diabetes. These strategies involve plasmid DNA designed to
weaken pre-existing beta-cell autoimmunity through delivery of anti-inflammatory cytokines,
chemokines, and other immune cell manipulating agents. The goal of these therapies is to
reduce clinical symptoms and autoimmune outcome.
2.1. Cytokine gene therapies
Cytokine gene therapies are strategies that use engineered plasmid DNA to produce thera‐
peutic immune cytokines, which are a group of immune active molecules secreted by different
cells of the body. Some of these cytokines are considered beneficial for the suppression of
autoimmunity, and thus are applied to disease models to reduce clinical symptoms and
improve therapeutic effects. Studies of animals with spontaneous autoimmune diabetes have
revealed that an important group of autoreactive T cells that mediates islet beta-cell destruction
belongs to the T helper-1 type effector cell subset, and produces cytokines like interleukin-2
and interferon-gamma. On the other hand, regulatory T cells that control effector cells can
secrete interleukin-4, interleukin-10, and transforming growth factor-beta.
One of the earliest applications of cytokine-engineered plasmid DNA was gene-gun delivery
of murine interleukin-4 to prevent spontaneous type 1 diabetes [18]. The plasmid DNA was
delivered as three times two microgram within 4 weeks into 3-week-old nonobese diabetic
mice, which is the animal model system closest to human type 1 diabetes. Type 1 diabetes
incidence was reduced from 90% in controls to 20% at 34 weeks of age, and was associated
with T helper-2 type immune responses in the periphery and pancreas of mice. Two other
reports have shown that systemic delivery of plasmid DNA constructs coding for interleukin-4
can prevent insulitis, which is an inflammatory sign of immune cell infiltrating pancreatic islets
in nonobese diabetic mice [19, 20]. However, contradictory results have been reported. For
example, a report indicates that intramuscular electroporation delivery of 50 µg plasmid DNA
encoding interleukin-4 accelerated spontaneous type 1 diabetes in nonobese diabetic mice [21].
In addition to interleukin-4, interleukin-10-encoded plasmid DNA alone was also tested for
its diabetic suppressive effects. The plasmid DNA was delivered intramuscularly twice for a
total of 200 microgram into 3 and 5 week old female nonobese diabetic mice [22]. Although
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the severity of insulitis at 13 weeks of age was not improved, the incidence of diabetes was
markedly reduced to 50% at 35 week old compared to 90% with control mice. These results
show that the progression of autoimmune disease in mice can effectively be suppressed by
intramuscular DNA injection coding for anti-inflammatory cytokines alone. When the same
interleukin-10 encoded plasmid DNA was combined with a cationic polymeric carrier,
systemic administration could reduce the severity of insulitis in NOD mice markedly (15.7%)
compared with that of naked DNA injection (34.5%) and non-treated controls (90.9%),
suggesting an increased protective effect of the polymeric carrier in vivo [23].
Another report investigating the immune effects of interleukin-10 DNA showed that systemic
intramuscular administration of 200 microgram interleukin-10 plasmid DNA could alleviate
blood glucose and insulitis in a streptozotocin induced diabetic mouse model up to day 28
post injection [24]. In this model, pancreatic interleukin-1b and tumor necrotic factor-alpha
gene expression, serum interferon-gamma concentration, and the numbers of CD4+ and
CD8+ lymphocytes were decreased on day 28. A similar interleukin-10 construct was modified
by introducing nuclear factor kappa-B (NF-kB) binding sites into plasmid DNA to facilitate
nuclear transport of the plasmid after delivery into the cell [25]. A single injection of 50
microgram of the plasmid using polyethylenimine as a gene carrier in 5 week old mice reduced
the degree of insulitis and serum glucose levels in 100% of mice compared to 40% of the control
mice at 32 weeks of age. These results illustrate how plasmid DNA can be easily modified in
a generic manner to improve therapeutic efficacy.
As mentioned previously, nanoparticle technology has been used to condense plasmid DNA
into nanometer-size complexes to improve delivery. An interleukin-10 encoding plasmid DNA
was assembled into a cationic nanoparticle complex, and a single dose of 50 microgram DNA
was delivered intramuscularly into streptozotocin-induced diabetic mice [26]. Animals
showed higher serum levels of interleukin-10, suppression of interferon-gamma level,
reduction of islet insulitis, and lower blood glucose levels compared to those treated with
interleukin-10 plasmid alone or the nanoparticle alone up to week 6 post injection. Histology
of muscle showed that nanoparticles were biocompatible and did not cause a chronic inflam‐
matory response.
In addition to their use alone, delivery of both interleukin-4 and interleukin-10 DNA has also
been investigated. Combined delivery into nonobese diabetic mice of the two plasmid DNA
constructs encoding interleukin-4 and interleukin-10 (25 µg each) was done intravenously
using a degradable, cationic polymeric carrier, poly (alpha-(4-aminobutyl)-L-glycolic acid)
[27]. Overexpression of the two cytokine messenger RNAs was confirmed in the liver of mice
5 days after delivery. Six weeks after injection, 75% of observed islets were intact compared
with less than 3% in the control group, and development of diabetes was prevented in 75% of
treated animals at 30 weeks of age, compared to 20% in control mice receiving plasmid DNA
coding for a single cytokine or vector control alone. The results indicated that the interleukin-4
and interleukin-10 plasmid DNAs had synergistic effects on the prevention of autoimmune
diabetes. A report from the same research group showed that a ‘chimeric’ plasmid expressing
both of the interleukin-4 and interleukin-10 under controls of two CMV promoters could also
reduce insulitis in the same system [28].
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More recently, a research group also reported packaging plasmid DNA constructs coding for
interleukin-4 and interleukin-10 into cationic nanomicelles to prevent type 1 diabetes [29]. A
single intramuscular dose of 50 microgram of the complex reduced levels of blood glucose and
insulitis up to 6-week post delivery in 5-week-old streptozotocin-induced diabetic mouse. It
was found that levels of diabetes-associated cytokines like tumor necrotic factor-alpha and
interferon-gamma were also reduced, which suggested suppression T helper-1 effector cells
by the cytokine/cationic nanomicelle complex therapy. Notably, plasmid DNA coding for
interleukin-4 and interleukin-10 has also been used as adjuvant to promote the therapeutic
effect of DNA vaccines in a murine model for type 1 diabetes, which will describe later in this
chapter in the ‘Glutamic Acid Decarboxylase DNA Vaccines’ section.
In addition, a number of studies have reported that injection of plasmid DNA coding for
cytokines normally considered pro-inflammatory can prevent diabetes. These results reflect
the multifaceted role of cytokines on immune response [30], which could be dependent on
dosage and time of administration. For example, administration of interleukin-18, also known
as interferon-gamma inducing factor, can prevent diabetes in NOD mice [31, 32]. However, it
was also shown that intramuscular electroporation of 2 x 100 microgram plasmid DNA coding
for interleukin-18 into 4-6-week-old nonobese diabetic mice aggravates diabetes [33]. Another
report showed that intraperitoneal administration of 30 microgram of plasmid DNA encoding
interferon-gamma promotes insulitis in reovirus type-2 induced diabetic mice compared to
controls [34]. This is in contrast with another report showing that injection of interleukin-12
induces interferon-gamma that prevents diabetes in NOD mice [35]. Together, these results
suggest that there is risk associated with direct delivery of cytokines for the treatment of type
1 diabetes. This possibility is suggested by a phase I clinical trial where new onset patients
with type 1 diabetes received a combination treatment of interleukin-2 and the immunosup‐
pressant rapamycin. The treatment had shown efficacy in preventing disease in mice, but it
accelerated disease in humans [2].
2.2. Chemokine gene therapies
Chemokines are a family of small chemotactic cytokines secreted by cells [36]. Their name is
derived from their ability to induce directed chemotaxis, or directed cell migration, in
responsive cells. Some chemokines are considered pro-inflammatory and can be induced
during an immune response to recruit cells of the immune system to a site of infection, while
others are considered homeostatic and are involved in controlling the migration of cells during
normal tissue maintenance and inhibiting abnormal inflammation like pathological autoim‐
mune response.
Chemokines are involved in pathogenesis of autoimmune disease because they can selectively
recruit various subsets of immune lymphocytes [37, 38]. Based on structural motifs near their
N-terminal cysteine residue [C], chemokines are divided into four subfamilies, termed CXC,
CX3C, C, and CC. The function of chemokines is modulated by the type of chemokine receptors
they bind to as ligands on the surface of cells, and studies have shown that chemokines and
chemokine receptors are involved in the pathogenesis of autoimmune diseases like type 1
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diabetes. Chemokine gene therapies for type 1 diabetes use anti-inflammatory chemokines as
well as inhibitors of pro-inflammatory chemokine binding.
With regard to blocking strategies, CXC ligand-10 is an example of a chemokine associated
with the pathogenesis of various T helper-1 dominant responses involved in autoimmune
diseases, e.g., experimental autoimmune encephalomyelitis, rheumatoid arthritis, and type 1
diabetes. It was found that, in type 1 diabetic adult patients, elevated levels of serum CXC
ligand-10 are associated with high-risk of disease in latent diabetic subjects [39]. This finding
was translated in animal models where blockade or neutralization of the CXC ligand-10 can
prevent type 1 diabetes in nonobese diabetic mice [40]. In virus-induced diabetic mice, virus
infection results in rapid and differential expression of CXC receptor-3 and CXC ligand-10,
which plays a dominant role in programming the ensuing autoimmune disease [41]. The
blockade of CXC ligand-10 by using anti CXC ligand-10 monoclonal antibodies successfully
aborts severity of antigen-specific injury of pancreatic beta cells and abrogates type 1 diabetes.
Mechanistically, the blockade impedes the expansion of peripheral antigen-specific T effector
cells and hinders their migration into the pancreas. A similar effect of the antibodies was
confirmed in a cyclophosphamide accelerated model of type 1 diabetes [40].
Based on these reports, plasmid DNA encoding the CXC ligand-10 was constructed to induce
production of anti-CXC ligand-10 antibodies in the host [42]. The aim was to avoid side-effects
associated with direct injection of antibodies. Intramuscular electroporation of 100 microgram
of the plasmid DNA at 4 and 6 weeks of age induced synthesis of anti CXC ligand-10 antibodies
in vivo, and suppressed the incidence of spontaneous diabetes which went from 75% in control
mice down to 25% in treated mice at 30 weeks of age. Although this treatment did not inhibit
insulitis or alter the immunological response, it enhanced the proliferation of pancreatic beta
cells and resulted in an increase of beta-cell mass.
A subsequent report from the same research group showed that combining complete Freund’s
adjuvant with plasmid DNA encoding the CXC ligand-10 could reverse diabetes [43]. Intra‐
muscular electroporation combined with complete Freund’s adjuvant was used to treat new-
onset female nonobese diabetic mice with blood glucose levels higher than 250 mg/dL. Diabetes
incidence was reduced from 70% in control mice to 20% in treated mice 10 weeks after plasmid
DNA delivery. In contrast, mice receiving complete Freund’s adjuvant and control plasmid
DNA did not show disease reversal. In mice that were treated successfully, residual beta-cell
mass was significantly increased, and some beta-cells were in a proliferative state. Although
systemic cytokine profiles were unaffected, the frequency of regulatory T cells expressing CXC
receptor-3 was significantly increased in local pancreatic lesions and possibly associated with
the regulation of anti-islet autoimmunity.
Another research group found that intra-pancreatic CC ligand-4 levels are increased in a model
of diabetes protection by interleukin-4 treatment in female nonobese diabetic mice [44]. The
protective effect of CC ligand-4 was confirmed by abrogation of diabetes suppression after
injection of anti-CC ligand-4 antibodies [45]. These result led to studies using CC ligand-4-
encoded plasmid DNA therapy which showed that gene-gun delivery of 1 microgram of the
plasmid DNA protects against type 1 diabetes in NOD mice, with diabetes rates reduced from
75% in control mice to 30% at 35 weeks of age when treated weekly from week 3 to 14, and
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from 80% in control mice down to 30% when treated weekly from week 9 to 14 [45]. Data also
indicated that plasmid DNA delivery could both prevent and treat type 1 diabetes. This
protection was associated with a T helper-2-like response in the spleen and pancreas, decreased
recruitment of activated CD8 T cells to islets accompanied by diminished CC receptor-5
expression on CD8 T cells, and increased regulatory T cell activity in the draining pancreatic
lymph nodes.
To summarize, plasmid DNA encoding CC ligand-4 and CXC ligand-10 have been tested for
their type 1 diabetic suppressive effects in spontaneous diabetic mouse models. Diabetes
suppression is associated with decreased CD8 T lymphocyte activity and increased CD4 T
regulatory cell activity. These results suggest a possible clinical application of chemokine
ligand gene therapies, although they are anticipated to have possible side effects associated
with systemic immunotherapies.
2.3. Other cell-manipulating gene therapies
Several immune cell populations have deficiencies in type 1 diabetes, such as CD4 T lympho‐
cytes, CD8 T lymphocytes, B lymphocytes, dendritic cells, macrophages, and NK cells in both
nonobese diabetic mice and human patients [46, 47]. The goal of cell-manipulating gene
therapy is to increase the diabetic suppressive function of cells like T regulatory or T helper-2
lymphocytes, which are considered important not only for therapeutic purposes, but also for
playing a determining role in the development of type 1 diabetes.
As mentioned at the beginning of this chapter, type 1 diabetes is a T helper-1-mediated
autoimmune disease and strategies suppressing the function of these cells can be expected to
have an impact on disease progression. One of these strategies is the delivery of galectin-9, a
carbohydrate-binding protein that regulates T helper-1 cells and induces their apoptosis
through the galectin-9 receptor. Apoptosis, or programmed-cell-death, is a constantly ongoing
process in steady state in vivo and helps maintain tissue and immune homeostasis. Mice treated
with plasmid DNA coding for galectin-9 were significantly protected from diabetes: intrave‐
nous delivery of 2 x 100 microgram bi-weekly protected 85% of mice from diabetes versus 55%
in controls [48]. Analysis of immune responses showed that the T helper-1 cell population was
markedly decreased in spleen, pancreas, and pancreatic lymph nodes of treated NOD-T1/2
double transgenic diabetic mice, indicating a suppressive role of galectin-9 on pathogenic T
helper-1 cells. Splenocytes from treated mice were also less responsive to mitogenic stimula‐
tion than splenocytes from the control group. Data indicated that galectin-9 DNA may
downregulate T helper-1 immune response in diabetic mice and could be used as a therapeutic
agent in autoimmune diabetes.
In contrast with galectin-9, decoy receptor 3 inhibits apoptosis. The membrane protein is a
member of the tumor necrosis factor receptor superfamily, and regulates immune responses
by neutralizing apoptotic signals transmitted through CD95 (Fas receptor), lymphotoxin beta-
receptor, and death receptor 3 on target cells. As a result, transgenic expression of decoy
receptor 3 in pancreatic beta cells protects nonobese diabetic mice from autoimmune diabetes
[49]. When decoy receptor 3 is delivered systemically as plasmid DNA, it inhibits insulitis and
diabetes by modulating immune responses. For example, four weekly intravenous injections
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of 100 microgram of plasmid DNA coding for decoy receptor 9 into nonobese diabetic mice
was reported to reduce diabetes incidence from 90% in controls to 30% when treated at 4 weeks
of age, 45% (started at 7 week old), and 70% (as Fc-fusion form, started at 12 week old) in 35-
week-old female nonobese diabetic mice [50]. Treated mice showed less splenocyte prolifera‐
tion and adoptive transfer of the cells ameliorated diabetes. Treated NOD-T1/2 mice had
reduced T helper-1, T helper-17, and increased T helper-2 immune responses in vivo. Data also
indicated that immune modulation by decoy receptor 3 may have been the result of differen‐
tiation and maturation of dendritic cells that subsequently regulated T effector differentiation
and function.
Cell migration is another process that plays a role in pancreatic beta cell destruction. In this
regard, plasmid DNA coding for CD44, which is a protein associated with cell migration and
delivery of apoptotic signals by inflammatory cells, was investigated for the suppression of
diabetes. It was found that subcutaneous implants of a silicone tube filled with wound dressing
sponge carrying CD44 encoded plasmid DNA could attenuate diabetes in a transfer model
[51]. Diabetes was induced in male nonobese diabetic mice by transfer of diabetogenic
splenocytes from female diabetic mice and was reduced from 90% in controls to 20-30% 12
weeks after two implants. Here the mechanism of treatment was not thought to be strictly a
gene therapy effect, but rather induction of anti-CD44 antibodies that inhibited CD44 function.
An increasing body of evidence points to a possible relationship between the central nervous
system and diabetes [52]. For example, the pancreatic autoantigen glutamic acid decarboxylase
is an enzyme responsible for synthesis of the neurotransmitter gamma-aminobutyric acid
(GABA) in the peripheral and central nervous system. Notably, at least two neurotransmitter-
related peptides have been used successfully as plasmid DNA immunotherapies for type 1
diabetes.
The first peptide is calcitonin gene-related peptide (CGRP), which has been found to play an
important role in the regulation of T lymphocytes and in protecting cells from reactive oxygen
species. It was found that a single injection of 200 microgram plasmid DNA encoding the
peptide delivered intramuscularly using electroporation could significantly ameliorate
hyperglycemia and insulin deficiency [53]. The treatment decreased diabetes incidence from
73% in controls to 23% at 28 days post delivery in a streptozotocin-induced diabetic model.
The gene transfer also significantly inhibited T cell proliferation and secretion of the T helper-1
cytokine interferon-gamma, increased the levels of the T helper-2 cytokine interleukin-10, but
had no effect on interleukin-4 and transforming growth factor-beta secretion. Therefore,
calcitonin gene-related peptide gene transfer appears to ameliorate streptozotocin-induced
diabetes through immune deviation.
The  second  peptide  is  named  vasoactive  intestinal  peptide  (VIP)  and  functions  as  a
neuromodulator  and  neurotransmitter  [54].  The  peptide  is  a  potent  vasodilator  that
regulates smooth muscle activity, epithelial cell secretion, and blood flow in the gastrointes‐
tinal  tract.  Importantly,  a  body  of  evidence  points  to  a  significant  role  of  vasoactive
intestinal  polypeptide  in  regulating  immune  responses.  The  peptide  acts  as  a  potent
endogenous anti-inflammatory molecule and promotes the activity of  T regulatory cells,
which  makes  it  a  promising  candidate  for  the  treatments  of  inflammatory  and autoim‐
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mune  diseases,  such  as  septic  shock,  arthritis,  multiple  sclerosis,  Crohn  disease,  and
autoimmune  diabetes  [55,  56].  For  example,  a  single  intramuscular  injection  of  300
microgram  of  vasoactive  intestinal  polypeptide-encoding  plasmid  DNA  significantly
reduced  the  incidence  of  cyclophosphamide  accelerated  diabetes  in  female  nonobese
diabetic mice, from 70% in control to 30% on day 33 post delivery in 8-10-week-old mice
[57]. A subsequent report in a different model system indicated that injection of the peptide
could activate FoxP3+CD4+CD25high T regulatory cells and protect against acute graft-versus-
host disease in a mouse model of allogeneic bone marrow transplantation [58].
2.4. Summary of Section 2
Section 1 covers plasmid DNA encoding small protein molecules like cytokines, chemokines,
peptides and other immune cell-manipulating agents with therapeutic effects on preclinical
type 1 diabetes (Table 1). These approaches belong to systemic treatments and inevitably bear
the risks associated with nonspecific immune suppression and chronic complications resulting
from interference with the host immune system. Nonetheless, if used as adjuvants or supple‐
ments to pancreatic autoantigen-targeting therapies like DNA vaccines, these approaches
could be used selectively in DNA-based combination therapies. We provide examples of such
approaches in Section 2 of this chapter.
3. DNA vaccine immunotherapies
Plasmid DNA vaccine-based immunotherapy is a promising therapeutic field for treatment of
type 1 diabetes. Clinical proof of concept has already been provided with results from phase
I/II trials where individuals with new-onset type 1 diabetes were treated with proinsulin-
encoding plasmid DNA [15]. Nevertheless, although beneficial effects were observed, it is clear
that efficacy must be significantly improved. Improving efficacy will be likely dependent on
the ability to modulate both the innate immune system, through activation of tolerogenic
antigen-presenting cells like dendritic cells, and the adaptive immune system, through
activation of various populations of regulatory cells. DNA vaccines are particularly well
positioned to achieve this goal because plasmid DNA is information-based, and can encode
molecules that affect the immune system in different manners. The challenge is to identify
which combination of functions should be delivered together with a pancreatic autoantigen
to treat disease with maximum efficacy and safety.
Several beta cell autoantigens have been tested in mice for induction of immune tolerance by
DNA vaccines and will be discussed in this section. Immune mechanisms associated with the
therapeutic effects of DNA vaccines can be complex because of the variety of cells that can
process the information encoded by plasmid DNA. Regardless, the major goals are to induce
diabetic suppressive dendritic cells, T regulatory lymphocytes, and the cell death and inacti‐
vation of T effector lymphocytes that destroy pancreatic beta cells.
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Categories Encoded Products Immune Responses Trials References
Gene Therapies
Cytokines IL-4 T helper-2 Preclinical [18-21]
IL-10 T helper-2 Preclinical [22-26]
IL-4 + IL-10 as
Nanoparticle T helper-2 Preclinical [27-29]
Chemokines C-C Motif Ligand 4 T helper-2, Tregs Preclinical [45]
C-X-C Motif Ligand 10 Tregs Preclinical [42,43]
Cellular Galectin-9 T helper-2 Preclinical [48]
Manipulations Decoy Receptor 3 T helper-2, DCs Preclinical [50]
CD44 Antibodies Preclinical [51]
CGRP T helper-2 Preclinical [53]
VIP Tregs Preclinical [57]
DNA Vaccines
Insulin B chain T helper-2 Preclinical [60,67]
Insulin B Chain + IL-4 T helper-2 Preclinical [61]
Proinsulin + Anti-CD154 CD25+ Tregs Preclinical [62]
Proinsulin DNA + Peptide CD25- Tregs Preclinical [63]
Proinsulin + PRP III CD25+ Tregs Preclinical [64]
Pre-proinsulin + B7-1wa ? Preclinical [65]
Proinsulin ? Preclinical,Clinical [15,66,68]
Proinsulin + Anti-CD3 T helper-2, CD25
+
Tregs Preclinical [71]
HSP 60 T helper-2 PreClinical [79]
HSP 65 T helper-2, Tregs Preclinical [80,81]
Secreted GAD65, GAD65 T helper-2 Preclinical [84,85,88,92]
GAD65-Ig Fc +
IL-4/IL-10/IL-4 & IL-10 T helper-2 Preclinical [86,87]
GAD65 + Anti-CD3 Tregs Preclinical [94]
Secreted GAD65 + BAX Tregs, DCs Preclinical [97-99]
IA-2 + IL-4 Tregs? Preclinical [101]
GPI + lysosome nTregs Preclinical [102]
Table 1. Plasmid DNA Based Immunotherapies for Type 1 Diabetes. The table summarizes plasmid DNA based
immunotherapies under two categories: Gene therapies and DNA vaccines. Immunotherapies are listed according to
their category, type of immune response and trial. Abbreviation: IL, interleukin; CD, cluster of differentiation; PRPIII,
pancreatic regenerating protein III; CGRP, calcitonin gene-related peptide; VIP, vasoactive intestinal polypeptide; HSP,
heat shock protein; GAD, glutamic acid decarboxylase. IA, insulinoma associated protein; Tregs, T regulatory cells; DCs:
dendritic cells.
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3.1. Insulin DNA vaccines
Thus far, the only DNA vaccine that has been tested in both preclinical and clinical trials is a
plasmid DNA construct coding for intracellular proinsulin, which is a partially processed non-
functional form of insulin. Insulin is not only the hormone produced by beta-cells that controls
carbohydrate and fat metabolism in the body, it is also a main target autoantigen in autoim‐
mune diabetes and the presence of anti-insulin autoantibodies can be an indication of disease
initiation [59]. DNA vaccines coding for different forms of insulin have been investigated for
type 1 diabetes immunotherapy since the late 1990’s. The first report to demonstrate efficacy
used a virus-induced diabetic mouse model system, and showed that intramuscular injection
of plasmid DNA encoding the insulin B chain reduces the incidence of diabetes (blood glucose
> 350 mg/dL) from 100% down to 50% [60]. The DNA vaccine induced insulin B-chain specific
CD4+ T regulatory cells that secreted interleukin-4, and locally reduced autoreactive activity
of cytotoxic T lymphocytes in the pancreatic draining lymph nodes. Further work showed that
co-delivery of interleukin-4 was required to prevent diabetes onset in male nonobese diabetic
mice [61].
Two isoforms of insulin are synthesized in rodent animals, insulin I in islets and insulin II in
both islets and thymus while humans have only one form of insulin. The pancreatic beta cells
synthesize proinsulin before converting it to functional insulin. In that regard, intranasal
delivery of plasmid DNA encoding mouse proinsulin II together with injection of an anti-
CD154 (also named CD40 ligand) antibody to prevent T cell activation was reported to prevent
type 1 diabetes in nonobese diabetic mice [62]. Delivery of 300 microgram DNA and 50
microgram antibody over a 2-week interval at 4 weeks of age synergistically prevented
diabetes, reducing disease incidence from 100% diabetic down to 0% in 40-week old mice.
Injection of the anti-CD154 antibody alone reduced the incidence to 50%. However, delivery
of the DNA vaccine alone did not reduce diabetes incidence, even though it could induce T
regulatory cells and reduce insulitis.
Another report has shown that co-delivery of 50 microgram plasmid DNA encoding human
proinsulin together with 100 microgram insulin peptide twice over a 2-week interval could
prevent diabetes until 24 weeks of age in 6 week old nonobese diabetic mice. In contrast, DNA
or peptide alone did not prevent disease [63]. Results also indicated induction of CD4+CD25-
islet specific T regulatory cells producing transforming growth factor-beta only in the co-
immunization group.
In another study, a DNA vaccine encoding proinsulin and pancreatic regenerating (Reg) III
protein resulted in a significant reduction of hyperglycemia and diabetes incidence with
increased serum insulin in a streptozotocin- induced mice model [64]. The treatment also
restored the balance of T helper-1/T helper-2 cytokines, expanded CD4+CD25+Foxp3+ T
regulatory cells, and attenuated insulitis by inhibiting activation of nuclear factor-kappa B (NF-
κB) in the pancreas, which is thought to promote the regeneration of islet beta cells.
Cytotoxic T lymphocyte antigen 4 (CTLA-4 or CD152) is a strong negative regulator of T cell
activity and another example of an immunomodulator that can be co-delivered with an
autoantigen. Like CD28 (a positive regulator), CTLA-4 binds to B7-1 and B7-2. It was found
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that a single amino acid substitution in B7-1 (denoted B7-1wa) could abrogate specific binding
to CD28 but not to CTLA-4. Co-delivery of B7-1wa and preproinsulin I encoded by plasmid
DNA abrogated reactivity to insulin and ameliorated type 1 diabetes in nonobese diabetic mice,
although delivery of either preproinsulin I or B7-1wa alone did not suppress the disease [65].
Interferon-gamma and interleukin-4 were both depressed, arguing against a T helper-2 bias,
but reactivity to glutamic acid decarboxylase 65 was not altered. Suppressor cells were not
identified, suggesting induction of tolerance to insulin by either T cell anergy or deletion in
this model.
Among the most promising reports of insulin DNA vaccination is a plasmid DNA construct
encoding mouse proinsulin II that could reduce the incidence of diabetes in nonobese diabetic
mice when administered intramuscularly to prediabetic 8-week old mice (prophylactic
setting), and to diabetic mice older than 12-week (therapeutic setting) with blood glucose > 170
mg/dL [66, 67]. The efficacy of the vaccine was improved by increasing the level of expression
of insulin, frequency of dosing, dosage, and subcelullar localization modification of the
autoantigen to the intracellular compartment instead of being secreted. In the prophylactic
setting, 8 weekly injections of 50 microgram of the DNA vaccine decreased the incidence of
diabetes from 80% in the control group down to 45% in 25-week old mice. The treatment caused
increased numbers of interferon-gamma secreting cells and a decrease in insulin autoantibod‐
ies. In the therapeutic setting, the DNA vaccine reduced diabetes from 100% in the control
groups down to 25% in treated mice 25 weeks post treatment initiation. The treatment induced
increased numbers of insulin-specific interferon-gamma-producing T cells and levels of
interleukin-10, which suggested the possible induction of T regulatory-1 cells. Adoptive
transfer experiments indicated that the protection was not mediated by the induction of
CD4+CD25+ T regulatory cells.
Most important, a similar DNA vaccine encoding human proinsulin was used in phase I/II
clinical trials and has been the only human trial of a DNA vaccine for diabetes conducted to
date [68, 69]. Construct BHT-3021 was delivered intramuscularly using four doses of plasmid
DNA, i.e., 0.3, 1, 3 and 6 milligram, administered once a week for 12 weeks. The interim results
for the 1 milligram dose showed pancreatic beta-cell preservation, demonstrated by a mean
17% increase in C-peptide levels with BHT-3021 by week 15 after enrollment, whereas placebo
patients experienced a mean 42% decrease in C-peptide. Evidence for immune tolerance was
suggested by a mean 17% reduction in anti-insulin antibodies, and 25% reduction in anti-
glutamic acid decarboxylase 65 antibodies by week 15 after enrollment, whereas placebo
patients experienced a mean 6% and 4% increase, respectively. The most recent report of the
trial claimed that BHT-3021 could preserve C-peptide levels for at least six months and one
year in some of the patients from the point of initiation of the therapy [15]. These results
together with its favorable side-effects profile appear to be somewhat comparable to those
reported with anti-CD3 monoclonal antibody, and the glutamic acid decarboxylase 65 protein
vaccines for type 1 diabetes.
However, thus far, no immunotherapy alone has been reported to cause long term remission
of clinical type 1 diabetes. This was confirmed with the announcements in 2011 of the failure
of three phase III clinical trials for type 1 diabetes that tested two anti-CD3 monoclonal
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antibodies and a GAD65 protein vaccine. The need to increase therapeutic efficacy has
generated an increased interest in combination immunotherapies [70-72]. Indeed, it is reason‐
able to anticipate that a variety of synergistic and additive effects may be induced by combining
different agents. For example, combination treatment with anti-CD3 epsilon specific antibody
and intranasal delivery of proinsulin peptide could reverse recent onset diabetes in nonobese
diabetic mice as well as in a virus-induced diabetic mouse model with much higher efficacy
than monotherapy using anti-CD3 or peptide alone [71]. Protection was associated with
expansion of CD25+ Foxp3+ and insulin specific T regulatory cells producing protective
cytokines, such as interleukin-10, transforming growth factor-beta, and interleukin-4. In
addition, these cells can transfer dominant tolerance to recent onset diabetic recipients, and
suppress heterologous autoaggressive CD8 T cell responses. While animal studies do provide
a rationale for combining therapies, there are hurdles that still need to be overcome for
translation to the clinic. For example, the possibility of unforeseen drug interactions is not in
the interest of pharmaceutical and biotech companies and could stop them from evaluating
their drugs in combination trials [72].
3.2. Heat shock protein 60 /65 DNA vaccines
Heat shock protein 60 (HSP60) is a 60-kilodalton mammalian protein that promotes the proper
folding of mitochondrial proteins and a possible autoantigen in type 1 diabetic children and
murine models [73, 74]. Epitope scanning of heat shock protein 60 with antibodies identified
peptide DiaPep277 with the amino sequence VLGGGVALLRVIPALDSLTPANED as an
immunodominant epitope in type 1 diabetic child patients [75, 76]. From an immunological
standpoint, mammalian heat shock proteins can also act as damage-associated molecular
patterns that are released or presented by dying cells and can activate antigen-presenting cells
of the innate immune system [77]. Heat shock proteins activate macrophages and dendritic
cells through Toll-like receptor 4, which belongs to a class of membrane-bound proteins that
act as sensors for immune cell activation, and promote proinflammatory effector immune
responses. Paradoxically, heat shock proteins can also mediate anti-inflammatory response
through Toll-like receptor 2 on T cells, and DiaPep277 peptide functions through a Toll-like
receptor 2-mediated mechanism [78].
Plasmid DNA coding for heat shock protein 60 has been shown to prevent type 1 diabetes in
mice. For example, two times 100 microgram intramuscular injections of plasmid DNA coding
for mammalian heat shock protein 60 into 4-week old nonobese diabetic mice suppressed
cyclophosphamide-accelerated diabetes, with 30% of treated mice developing diabetes
compared with 60% in vector treated controls [79]. Disease prevention was associated with
reduced T cell proliferation, increased in interleukin-10 and interleukin-5 secretion, and
decreased interferon-gamma secretion, which suggested a shift from a T helper-1 like toward
a T helper-2 like immune response.
In addition, plasmid DNA encoding mycobacterial 65-kilodalton heat shock protein could also
affect diabetes by causing decreased insulitis when injected intramuscularly in three doses
(100 microgram each) at 2-week intervals into 6- to 8-week-old, streptozotocin-induced
diabetic C57BL/6 mice [80]. The treatment was associated with the appearance of a regulatory
Type 1 Diabetes546
cell population in the spleen, with higher production of interleukin-10 in the spleen and islets,
and with a decreased infiltration of CD8 T lymphocytes in the islets. The same DNA vaccine
with the same dose and delivery reduced the occurrence of diabetes from 100% to 33% in 28-
week old nonobese diabetic mice when injected at 4-week of age, and was associated with a
reduction in CD4 and CD8 T cells infiltration, appearance of CD25 cells, and increased levels
of interleukin-10 in pancreatic islets [81].
3.3. Glutamic acid decarboxylase DNA vaccines
Glutamic acid decarboxylase 65 is an enzyme that catalyzes the synthesis of gamma-amino‐
butyric acid (GABA) which acts as a neuroinhibitor as well as an immunoregulatory molecule.
Evidence indicates that glutamic acid decarboxylase 65 may have a critical early role in
mediating islet beta cell destruction and is an important target autoantigen in type 1 diabetes.
Detection of anti-glutamic acid decarboxylase antibodies in the sera of prediabetic patients is
a reliable predictive marker for the progression to overt diabetes, and anti-glutamic acid
decarboxylase reactivity can be detected in nonobese diabetic mice model early in the disease
process [82, 83].
Plasmid DNA vaccines coding for glutamic acid decarboxylase 65 are currently at the preclin‐
ical stage. The first report of a beneficial effect in nonobese diabetic mice showed that plasmid
DNA encoding wild-type intracellular or engineered secreted glutamic acid decarboxylase,
i.e., a fusion of the interleukin-2 signal peptide with a truncated form of human glutamic acid
decarboxylase 65, caused decreased insulitis compared to plasmid vector alone when deliv‐
ered intramuscularly, and was accompanied by elevated secretion of interleukin-4 by spleno‐
cytes [84]. A subsequent report indicated that only the DNA vaccine encoding secreted
glutamic acid decarboxylase could suppress cyclophosphamide-accelerated diabetes in 4-
week old female nonobese diabetic mice with a tendency to increase T helper-2 like activity
when two times 400 microgram were delivered intramuscularly over 3 days [85].
A report published the same year corroborated the notion that secretion of glutamic acid
decarboxylase encoded by a DNA vaccine is important to ameliorate diabetes in mice [86]. In
this report, plasmid DNA was engineered to encode a secreted fusion protein of a truncated
form of glutamic acid decarboxylase 65 and an IgG Fc fragment as well as interleukin-4.
Intramuscular injection of 50 microgram of the vaccine effectively prevented diabetes in
nonobese diabetic mice treated at early (4-week old, 3 times weekly) or late (12-week old, 4
times weekly) preclinical stages of diabetes. Diabetic onset reduction went from 75% in controls
to 25% in treated animals at week 50. Protection was dependent on interleukin-4 as well as
endogenous interleukin-4, and associated with the induction of glutamic acid decarboxylase
65 specific regulatory T helper-2 cells [87]. In addition, the same strategy was used with insulin
as the target autoantigen. In this case, the DNA vaccine encoding an insulin B chain/IgG Fc
fusion protein and interleukin-4 caused accelerated progression of insulitis and diabetes,
which correlated with increased numbers of interferon-gamma secreting T cells in response to
insulin B chain specific peptides. On the other hand, a group reported that a DNA vaccine
encoding full-length intracellular human glutamic acid decarboxylase 65 alone could prevent
spontaneous diabetes in nonobese diabetic mice when delivered at 4 or 10 weeks of age using
DNA Immunotherapies for Type 1 Diabetes
http://dx.doi.org/10.5772/55727
547
intramuscular injections of two times 50 microgram DNA [88]. Notably, disease prevention
was associated with CD28/B7 costimulation because co-expression of B7-1 or B7-2 and glutamic
acid decarboxylase 65 by the same DNA vaccine abrogated protection. Another study
investigated the relationship between endogenous expression levels of glutamic acid decar‐
boxylase in beta-cells and the efficacy of DNA vaccination [89]. Injection of plasmid DNA
coding for glutamic acid decarboxylase into mice with lower expression levels of the autoan‐
tigen resulted in the induction of autosuppressive regulatory cells characterized by increased
interleukin-4 production (T helper-2 like). In contrast, higher levels of the autoantigen favored
T helper-1-like autoaggressive responses characterized by increased the interferon-gamma
generation. Immunization with a DNA vaccine coding the glutamic acid decarboxylase and
interleukin-4 reduced the risk of augmenting autoaggression and thus increased the safety of
this immune-based therapy.
DNA vaccines encoding secreted glutamic acid decarboxylase combined with anti-inflamma‐
tory interleukins have also been applied to pancreatic transplant for type 1 diabetes. Survival
of syngeneic neonatal pancreata transplanted under the kidney capsule of nonobese diabetic
mice was promoted by intramuscular injection of a DNA vaccine encoding the secreted
glutamic acid decarboxylase 65/IgG Fc fusion and interleukin-4 plus interleukin-10 [90]. The
treatment consisted of 50 microgram of the vaccine delivered weekly for four weeks from the
age of 10 weeks with transplantation performed one week after the final DNA vaccination.
DNA vaccination protected syngeneic islet in transplanted mice, with 100% diabetic mice in
controls compared to 20% diabetes incidence in treated animals at 30 weeks of age and 15
weeks post transplant. Increased islet survival required co-delivery of both interleukin-4 and
interleukin-10 and correlated with a marked reduction in interferon-gamma reactivity as well
as an increase in interleukin-10 secreting T cells. These results made apparent the increased
difficulty in protecting exogenous syngeneic islet and the need for more stringent conditions
of vaccination in the transplantation setting.
Most DNA vaccines for type 1 diabetes have been delivered into muscle tissue. The main
rationale for using this route of delivery is that it permits administration of larger amounts of
DNA, but other routes may be more advantageous to induce tolerogenic responses. In that
regard, a report compared intramuscular, intradermal, and oral delivery of plasmid DNA
coding for the intracellular or secreted form of glutamic acid decarboxylase for prevention of
diabetes in 4-week-old nonobese diabetic mice [91]. Results indicated that both intradermal
and oral deliveries were more effective than intramuscular delivery for delaying the disease.
Cytokine-specific ELISpot analysis indicated that immune responses induced by the DNA
vaccination were generally more dependent on the cellular localization of glutamic acid
decarboxylase antigen than on the delivery route, although ELISA indicated that intradermal
delivery of DNA is most likely to induce a T helper-2 like response.
In addition to route of delivery, the method used to administer a DNA vaccine can be beneficial
by increasing efficacy of DNA uptake and improving immune responses. For example, dermal
delivery of plasmid DNA using gene gun technology, which consists in shooting gold micro-
particles covered with DNA, can improve protection from diabetes. In this regard, gene-gun
delivery of 1 microgram of a DNA vaccine encoding the secreted glutamic acid decarboxylase
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65/IgG Fc fusion polypeptide into 10-week old nonobese diabetic mice was compared with
intramuscular injection of 50 microgram of the same vaccine [92]. Results indicated that, in
both cases, gene expression peaked at week 8 post deliveries and was maintained until at least
week 35 with more than 40% higher expression from the gene-gun delivery. However, only
gene-gun delivery protected mice from diabetes with 90% diabetic animals in controls down
to 50% diabetic mice at 35 weeks of age. In contrast, gene-gun administration of plasmid DNA
encoding intracellular glutamic acid decarboxylase 65 to 3-week old nonobese diabetic mice
did not suppress diabetes in nonobese diabetic mice [93]. The different results might be
attributed to the different subcellular localizations of the autoantigen.
As mentioned earlier, combination therapy is being increasingly considered as a means to
improve efficacy of immunotherapy for type 1 diabetes. Combining a DNA vaccine coding for
intracellular GAD65 with an anti-CD3 monoclonal antibody has been investigated in two
different mouse model systems for that purpose [94]. Results indicated that successful
treatment was observed in a virus-induced diabetic model (the RIP-LCMV-GP model) but not
the nonobese diabetic mouse. Efficacy was associated with an expansion of bystander sup‐
pressor T regulatory cells recognizing the C-terminal region of GAD65 and secreting interleu‐
kin-10, transforming growth factor-beta and interferon-gamma. These results also showed that
efficacy was associated with numbers of antigen-specific T cells available at time of treatment,
which was different beween the two animal models. The findings hold important implications
to predict the success of antigen-based clinical trials where responsiveness to immunotherapy
may vary from patient to patient.
Thus far, we have described in this section how DNA vaccines can be engineered to enhance
tolerogenic-like immune responses by co-delivering cytokine-encoding DNA, an antibody,
engineering subcellular localization of a target autoantigen, and choosing an effective route
and method of delivery. These results obtained by different laboratories illustrate the prom‐
ising potential of DNA vaccination as a safe, low-cost and patient-friendly means to treat
autoimmune diabetes and other immune-mediated inflammatory disorders. Yet, as with all
immunotherapies that seek means of improving the life of diabetic individuals, there is a
pressing need to improve treatment efficacy through the identification of novel molecular
adjuvants for the safe induction of immune tolerance.
Ideally, these adjuvants should attempt to mimic how immune tolerance is maintained in
steady state. Here, we briefly discuss plasmid-induced apoptosis as a possible means to mimic
physiological immune tolerance and to approach the “Holy Grail” of immunotherapy, namely,
the ability to suppress inflammation in a homeostatic manner. Apoptosis is a constantly on-
going form of cell death that produces fifty to seventy billion dead cells on a daily basis in an
average human adult [95]. Upon a given intrinsic or extrinsic signal, cells initiate the process
of apoptosis and become membrane-bound cellular fragments, or apoptotic bodies, which are
rapidly engulfed and processed by surrounding living cells. For many years, it was believed
that these apoptotic bodies had little effect on the immune system. Today, it has become clear
that apoptosis is an important physiological means to establish and maintain immune
tolerance in peripheral tissues. Apoptotic cells play a fundamental role as they not only serve
as a source of self-antigens, but also recruit antigen-presenting cells, secrete anti-inflammatory
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cytokines, and display tolerogenic molecules [96]. The remarkable capacity of apoptotic cells
to induce either tolerogenic immune responses or immunogenic responses depending on
signals received makes them attractive candidates to intervene in many disorders like
infectious diseases, cancer, and autoimmune diseases.
The first report of DNA vaccines designed for pro-apoptotic immunoregulation, i.e., anti-
inflammatory, used plasmid DNA coding for the pro-apoptotic BAX protein and intracel‐
lular or secreted glutamic acid decarboxylase, to prevent diabetes in the nonobese diabetic
mouse  [97].  Results  indicated  that  intramuscular  injection  of  the  BAX  cDNA  recruited
dendritic cells carrying vaccine-encoded protein in both spleen and lymph nodes. Further‐
more,  delivery of  two times 150 microgram plasmid DNA coding for  secreted glutamic
acid decarboxylase and BAX at 3 days interval into 4-week old mice prevented diabetes,
i.e, reduced the incidence from 93% in controls down to 47% in treated animals. In contrast,
the vaccines coding for BAX DNA alone or intracellular glutamic acid decarboxylase and
BAX did not prevent diabetes. Notably, ELISA results suggested that co-delivery of BAX
suppressed T helper-2 like activity,  which indicated that another cell  type was responsi‐
ble  for  disease  suppression.  Indeed,  a  subsequent  report  showed  that  delivery  of  both
secreted glutamic acid decarboxylase and BAX were required to induce CD4+CD25+FoxP3+
cells with contact dependent regulatory activity [98].
Importantly, additional studies revealed that increased CpG methylation of plasmid DNA
together with delivery of secreted glutamic acid decarboxylase and BAX DNA could act
synergistically to ameliorate recent onset diabetes in nonobese diabetic mice [99]. A weekly
intradermal injection of 50 microgram of the vaccine over eight weeks following early
hyperglycemia ameliorated diabetes at 40 weeks of age, from 90% diabetic mice in controls
down to 20% in treated mice. Remarkably, DNA hypermethylation caused increased numbers
of tolerogenic-like plasmacytoid dendritic cells in lymph nodes. It is hypothesized that
increased CpG methylation of plasmid DNA makes the DNA vaccine appear more mamma‐
lian-like to the immune system, as it is known that bacterial DNA has low levels of CpG
methylation that can act as an inflammatory signal [100]. Taken together these results indicate
that apoptosis-inducing DNA vaccination is a promising approach for treatment of type 1
diabetes.
3.4. Other DNA vaccines
DNA vaccines encoding less studied autoantigens have also been investigated. For example,
insulinoma-associated protein 2 (IA-2), which is expressed in islets, brain, and neuro-endocrine
cells, is a member of the protein tyrosine phosphatase family and targeted by autoimmune T
cells in type 1 diabetes. A DNA vaccine encoding insulinoma-associated protein 2 with or
without the combination of DNA coding for interleukin-4 and monocyte chemoattractant
protein-1 (MCP-1) was injected intramuscularly into pre-diabetic non-obese diabetic mice
using 3 x 100 microgram DNA delivered over four weeks [101]. The treatment could protect
mice from diabetes, from 60% in controls to 10-20% diabetic animals at 30 weeks of age. There
was no difference in efficacy between groups treated with the DNA vaccine alone or combined
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with interleukin 4/MCP1, and animals in both groups had fewer CD8 T lymphocyte counts in
spleen.
In another example, a DNA vaccine treatment strategy was designed to target an antigenic
peptide (glucose-6-phosphate isomerase, GPI) to the lysosomal compartment. A specific T cell
population termed 2.5mi+ T cells is known to share reactivity with the diabetogenic T cell clone
BDC-2.5 in the NOD mouse [102]. Lysosome targeting of single peptide epitope was sufficient
to induce protection against type 1 diabetes which was not the result of antigen-specific T cell
anergy. Typical T helper-2 cytokines like interleukin-10 or -4 were undetectable in 2.5mi+ T
cells, arguing against a mechanism of immune deviation. Instead, the expanded 2.5mi+ T cell
population produced interferon-gamma similar to 2.5mi+ T cells from naive mice. Protection
against diabetes induced by DNA vaccination was completely lost in NOD.CD28-/- mice, which
are largely deficient of natural T regulatory cells. Furthermore, diabetes onset was delayed in
T regulatory-reconstituted and DNA-treated NOD.SCID mice, although antigen-specific
Foxp3+ cells did not expand in response to DNA treatment. These findings indicated a T
regulatory-mediated protective mechanism that was independent of the expansion or de novo
generation of antigen-specific T regulatory cells.
3.5. Summary of section 3
DNA vaccination has been tested in clinical trials for treatment of new-onset type 1 diabetes
with encouraging results, but efficacy must be improved. The number and variety of strategies
that have been developed to improve efficacy of DNA vaccination for autoimmune diabetes
is a testament to the flexibility and potential of DNA vaccine immunotherapy.
4. Conclusion: Plasmid DNA as a promising immunotherapy for Type 1
diabetes
Plasmid DNA is a versatile vector platform permitting the seamless integration of different
immune modulators into a product that can be manufactured in a generic manner. As we have
seen in this chapter, plasmid DNA has been extensively investigated for the prevention and
treatment of type 1 diabetes in different animal model systems. Plasmid DNA-based gene
immunotherapies do not encode an autoantigen and act systemically to different degrees,
which could result in serious adverse events if used over time. Nevertheless, gene immuno‐
therapies could still be utilized as molecular adjuvants with DNA vaccines that target pan‐
creatic beta cell autoantigens. It is possible that different stages during progression of disease
will require different therapeutic agents or combinations thereof according to immune
responses to therapy. It is also anticipated that some strategies will be safer and more robust
than others, but there is unfortunately no animal model that can predict successful bench-to-
bedside translation of a given strategy. In that regard, immunological biomarkers and their
pre-clinical and clinical correlates will be needed to determine which strategies are most likely
to be effective in humans, and to what extent different immunotherapies might be combined.
Combinatorial therapies include co-delivery of DNA vaccines with gene therapy, peptide
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vaccines, monoclonal antibodies, and other adjuvant agents that have shown synergistic
effects. In one possible scenario, autoantigen-specific immunotherapies could be used over the
long-term as stand-alone treatments, with the occasional help of systemic immune modulators
depending on disease severity. Regardless of the strategy to be chosen, there is a strong case
to be made for including plasmid DNA immunotherapy in future treatments of type 1 diabetes.
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